Onconetix, Inc. Files 8-K

TL;DR

Onconetix (ONCO) filed an 8-K on 7/15. Nothing major, just standard reporting.

AI Summary

Onconetix, Inc. filed an 8-K on July 15, 2024, reporting other events and financial statements. The company, formerly known as Blue Water Biotech, Inc. and Blue Water Vaccines Inc., is incorporated in Delaware and headquartered in Cincinnati, Ohio.

Why It Matters

This filing provides an update on Onconetix, Inc.'s corporate activities and financial reporting, which is important for investors to stay informed about the company's status.

Risk Assessment

Risk Level: low — This is a routine filing that does not appear to contain significant new information or material events.

Key Players & Entities

• Onconetix, Inc. (company) — Registrant
• Blue Water Biotech, Inc. (company) — Former company name
• Blue Water Vaccines Inc. (company) — Former company name
• July 15, 2024 (date) — Date of report
• Cincinnati, Ohio (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.00001 — ch registered Common Stock, par value $0.00001 per share ONCO The Nasdaq Stock Mar
• $2.546 — tock at the original exercise prices of $2.546 and $1.09 per share, issued on August 1
• $1.09 — original exercise prices of $2.546 and $1.09 per share, issued on August 11, 2022 an
• $0.15 — n stock, at a reduced exercise price of $0.15 per share, in exchange for the Company'

Filing Documents

• ea0209387-8k_onconetix.htm (8-K) — 24KB
• ea020938701ex99-1_onconetix.htm (EX-99.1) — 10KB
• e99-1_001.jpg (GRAPHIC) — 3KB
• 0001213900-24-061151.txt ( ) — 213KB
• onco-20240715.xsd (EX-101.SCH) — 3KB
• onco-20240715_lab.xml (EX-101.LAB) — 33KB
• onco-20240715_pre.xml (EX-101.PRE) — 22KB
• ea0209387-8k_onconetix_htm.xml (XML) — 4KB

01 Other Events

Item 8.01 Other Events. As previously disclosed on a Current Report on Form 8-K filed on July 11, 2024 with the Securities and Exchange Commission, on July 11, 2024, Onconetix, Inc., a Delaware corporation (the " Company "), entered into a common stock preferred investment options exercise inducement offer letter (the " Inducement Letter ") with certain holders (the " Holders ") of existing preferred investment options (" PIOs ") to purchase shares of the Company's common stock at the original exercise prices of $2.546 and $1.09 per share, issued on August 11, 2022 and August 2, 2023, respectively (collectively, the " Existing PIOs "). Pursuant to the Inducement Letter, the Holders agreed to exercise for cash their Existing PIOs to purchase an aggregate of 7,458,642 shares of the Company's common stock, at a reduced exercise price of $0.15 per share, in exchange for the Company's agreement to issue new PIOs to purchase up to 22,375,926 shares of the Company's common stock (the " Inducement PIO Shares "), with the issuance of such Inducement PIO Shares being subject to stockholder approval. On July 15, 2024, the Company consummated the transactions contemplated by the Inducement Letter and on July 12, 2024 issued a press release to announce such closing (the " Press Release "). The Press Release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Press Release, dated July 15, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Onconetix, Inc. July 15, 2024 By: /s/ Karina Fedasz Name: Karina Fedasz Title: Interim Chief Financial Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR